Mechanistic studies revealed that this co-formulation upregulated PTEN levels, degraded BRD4, and ultimately downregulated c-Myc to curb the proliferation of BRAF inhibitor (BRAFi)-resistant melanoma cells. The gene discussed is BRD4; the disease is melanoma.